866-997-4948(US-Canada Toll Free)

Global Crohn's Disease (CD) Market 2015-2019

Published By :

Technavio

Published Date : Mar 2015

Category :

Diseases & Conditions

No. of Pages : 102 Pages


About CD

CD is an ongoing condition that causes inflammation of the digestive tract or the GI tract. CD may also be named as ileitis, granulomatous enteritis or colitis, regional enteritis, or terminal ileitis. The exact etiology of CD is unknown. Usually, CD affects the small intestine and the beginning of the large intestine. However, the disease can disturb any part of the GI tract, from the mouth to the anus. CD can occur at any age; however, it is usually first diagnosed in people in their teens and twenties.

TechNavio's analysts forecast the Global CD market to grow at a CAGR of 2.84 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global CD market for the period 2015–2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CD. The Global CD market can be divided into five segments: 5-ASA, Antibiotics, Biologicals, Corticosteroids, and Immunomodulators.

TechNavio's report, the Global CD Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global CD market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA      
 
Key Vendors

  • AbbVie
  • Astra Zeneca
  • Biogen Idec
  • Johnson & Johnson
  • Takeda Pharmaceutical
  • UCB

Other Prominent Vendors

  • Amgen
  • Boehringer Ingelheim
  • Celltrion
  • ChemoCentryx
  • Ferring Pharmaceuticals
  • Merck
  • Mitsubishi Tanabe
  • Novartis
  • Novo Nordisk
  • Pfizer

Market Driver

  • Increase in CD Prevalence
  • For a full, detailed list, view our report

Market Challenge

  • Multiple Patent Expiry
  • For a full, detailed list, view our report

Market Trend

  • Increase in Strategic Collaborations
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles

04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05. Introduction

06. Disease Overview
06.1 Understanding the Disease
06.2 Etiology
06.2.1 Autoimmune Reaction
06.2.2 Genes
06.2.3 Environment
06.3 Stages of CD
06.4 Epidemiology
06.4.1 Global
06.4.2 US
06.4.3 UK
06.5 Symptoms
06.5.1 Diarrhea
06.5.2 Fever & Fatigue
06.5.3 Abdominal Pain & Cramping
06.5.4 Perianal Disease & Blood in the Stool
06.5.5 Reduced Appetite & Weight Loss
06.6 Diagnosis & Testing
06.6.1 Early Tests and Exams
06.6.2 Endoscopy and Biopsy
06.6.3 Chromoendoscopy
06.6.4 Small Intestinal Imaging
06.7 Treatment
06.7.1 Medication
06.7.2 Diet & Nutrition
06.7.3 Surgery

07. CD Pipeline Landscape
07.1 Some of the emerging therapeutic options for CD:

08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 CD Market in the US
08.3.1 Market Size and Forecast
08.4 CD Market in Japan
08.4.1 Market Size and Forecast

09. Market Segmentation by Drug Class
09.1 Five Forces Analysis

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 AbbVie
18.2.2 Astra Zeneca
18.2.3 Biogen Idec
18.2.4 Johnson and Johnson
18.2.5 Takeda Pharmaceutical
18.2.6 UCB
18.3 Other Prominent Vendors

19. Key Vendor Analysis
19.1 AbbVie Inc.
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Product Segmentation by Revenue 2013
19.1.4 Product Segmentation by Revenue 2012 and 2013
19.1.5 Sales by Geography
19.1.6 Business Strategy
19.1.7 Key Developments
19.1.8 SWOT Analysis
19.2 AstraZeneca plc
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation by Revenue 2013
19.2.4 Business Segmentation by Revenue 2011-2013
19.2.5 Sales by Geography
19.2.6 Business Strategy
19.2.7 Key Developments
19.2.8 SWOT Analysis
19.3 Biogen Idec
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation by Revenue 2013
19.3.4 Geographical Segmentation by Revenue 2013
19.3.5 Business Strategy
19.3.6 Key Developments
19.3.7 SWOT Analysis
19.4 Johnson & Johnson
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation by Revenue 2013
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Geographical Segmentation by Revenue 2013
19.4.6 Business Strategy
19.4.7 Recent Developments
19.4.8 SWOT Analysis
19.5 Takeda Pharmaceuticals
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation by Revenue 2013
19.5.4 Business Segmentation by Revenue 2013
19.5.5 Geographical Segmentation by Revenue 2013
19.5.6 Business Strategy
19.5.7 Recent Developments
19.5.8 SWOT Analysis
19.6 UCB
19.6.1 Key Facts
19.6.2 Business Overview
19.6.3 Product Segmentation by Revenue 2013
19.6.4 Product Segmentation by Revenue 2012 and 2013
19.6.5 Geographical Segmentation by Revenue 2013
19.6.6 Business Strategy
19.6.7 Recent Developments
19.6.8 SWOT Analysis

20. Other Reports in this Series

List of Chart


Exhibit 1: Market Research Methodology
Exhibit 2: Overview of CD
Exhibit 3: Types of CD
Exhibit 4: Expected Number of Global CD Cases 2015-2022
Exhibit 5: Global Variation in Incidence Rates for CD in 2012 (in percent)
Exhibit 6: Prevalence of CD in the US
Exhibit 7: Incidence Rate of CD in the US
Exhibit 8: Symptoms of CD
Exhibit 9: CD: Diagnosis & Testing
Exhibit 10: CD: Treatment
Exhibit 11: Treatment Landscape for CD
Exhibit 12: CD: Treatment Pathway
Exhibit 13: CD Clinical Trial by Phase
Exhibit 14: CD Clinical Trial by Status
Exhibit 15: Snapshot of Global CD Market 2014
Exhibit 16: Global CD Market 2014-2019 (US$ billion)
Exhibit 17: CD Market in the US 2014-2019 (US$ billion)
Exhibit 18: CD Market in Japan 2014-2019 (US$ billion)
Exhibit 19: Global CD Market Segmentation by Drug Class
Exhibit 20: Benefits and Risks of ASA's
Exhibit 21: Global CD Market by Geographical Segmentation 2014
Exhibit 22: Approved Biologics for CD
Exhibit 23: AbbVie's Humira Global Revenue 2010-2013 (US$ million)
Exhibit 24: AstraZeneca Sales by Therapy Area 2013
Exhibit 25: Biogen's Tysabri Global Revenue 2011-2013 (US$ million)
Exhibit 26: Biogen's Tysabri Quarter Sales of 2014 (US$ million)
Exhibit 27: Johnson & Johnson Sales by Therapeutic Area (Pharmaceuticals) 2013
Exhibit 28: Johnson & Johnson Remicade Global Revenue 2010-2013 (US$ million)
Exhibit 29: Johnson & Johnson Stelara Global Revenue 2010-2013 (US$ million)
Exhibit 30: UCB's Cimzia Global Revenue 2010-2013 (US$ million)
Exhibit 31: AbbVie Inc.: Product Segmentation by Revenue 2013
Exhibit 32: AbbVie Inc.: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 33: AbbVie Inc.: Sales by Geography 2013
Exhibit 34: AstraZeneca plc: Business Segmentation by Revenue 2013
Exhibit 35: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 36: AstraZeneca plc: Sales by Geography 2013
Exhibit 37: Biogen Idec: Business Segmentation by Revenue 2013
Exhibit 38: Biogen Idec: Geographical Segmentation by Revenue 2013
Exhibit 39: Johnson & Johnson: Business Segmentation by Revenue 2013
Exhibit 40: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 41: Johnson & Johnson: Geographical Segmentation by Revenue 2013
Exhibit 42: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
Exhibit 43: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
Exhibit 44: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013
Exhibit 45: UCB: Product Segmentation by Revenue 2013
Exhibit 46: UCB: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 47: UCB: Geographical Segmentation by Revenue 2013

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *